Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/2020
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDr.Dhruti Avlani-
dc.date.accessioned2025-10-14T07:38:36Z-
dc.date.available2025-10-14T07:38:36Z-
dc.date.issued2024-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/2020-
dc.description.abstractABSTRACT Background: Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) pose significant worldwide challenges. Low oral bioavailability of antiretroviral s ( AntiRV), hinders their effectiveness in reaching infection sites and increasing the risk of relapse. Preventative measures like topical vaginal pre exposure prophylaxis (PrEP) are crucial in reducing HIV transmission for HIV negative individuals to lower their virus contraction risk during intercourse. Objectives: The first part of the project aimed to design and develop novel PrEP sispersible vaginal tablets ( DT composed of tenofovir disoproxil fumarate TDF loaded bio adhesive chitosan microparticles (T CM). The second part focused on formulating pessaries with TDF loaded bio adhesive sodium alginate ( S Alg ) microspheres (T AM) for intra vaginal administration to address the shortcomings associated with conventional oral dosage forms.en_US
dc.language.isoen_USen_US
dc.publisherKLE Academy of Higher Education and Research, Belagavien_US
dc.subjectIntra vaginal ; tenofovir; chitosan; sodium alginate; microparticles; vaginal tablet; pessaries; mucoadhesionen_US
dc.titleFormulation And Evaluation Of Vaginal Drug Delivery System Of Tenofovir: An Experimental Studyen_US
dc.typePhd Thesisen_US
Appears in Collections:Faculty of Pharmacy

Files in This Item:
File Description SizeFormat 
Dhruti Avlani.pdf20.2 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.